Search

Your search keyword '"J. M. Fitzpatrick"' showing total 2 results
Start Over Author "J. M. Fitzpatrick" Journal annals of oncology
2 results on '"J. M. Fitzpatrick"'

1. What Clinical and Non-Clinical Factors Influence Prostate Cancer Treatment Decisions? a National Clinical Survey

Author

Linda Sharp, J. M. Fitzpatrick, Harry Comber, and M. Camargo De Cancela

Subjects
Gangrene, medicine.medical_specialty, education.field_of_study, business.industry, Prostatectomy, General surgery, medicine.medical_treatment, Population, Hematology, urologic and male genital diseases, medicine.disease, Androgen deprivation therapy, Radiation therapy, Prostate cancer, Oncology, Amputation, medicine, Life expectancy, business, education
Abstract

Background Prostate cancer treatment remains controversial. Several population-based studies have revealed strikingly different treatment trends by patient age, suggesting treatment decisions may be influenced heavily by non-clinical considerations. To investigate factors considered important by clinicians we surveyed radiotherapists and urologists in Ireland. Materials and methods All radiotherapists and urologists were asked to complete a postal questionnaire involving patients scenarios rating 68 comorbid conditions (from ACE-27) in terms of their impact on treatment recommendations regarding radical prostatectomy (RP; urologists), radiotherapy (RT; radiotherapists) and androgen deprivation therapy (both). Respondents indicated which of 13 non-medical issues impacted on treatment. Results 24 urologists (56%) and 12 radiotherapists (46%) responded. Performance assessment tools were used by more radiotherapists than urologists (92% vs 20%). All urologists and 10 radiotherapists prescribed ADT. Conditions rated as having the greatest impact on RP or RT treatment decisions were similar: severe dementia, acute stroke and recent bypass or amputation for gangrene. Non-clinical factors with the greatest impact were: life expectancy (urologists: 100%; radiotherapists: 100%) and patient's preference (100%, 92%), followed by age for urologists (96%) and patient quality-of-life for radiotherapists (83%). Conditions impacting on ADT recommendations were: recent pulmonary embolia, acute stroke and cirrhosis. Conclusions Radiotherapists were more heterogeneous than urologists in their views on which clinical factors influence treatment decisions. Many conditions which strongly influence treatment are uncommon in patients, therefore unlikely to explain treatment variations. Our findings confirm clinicians consider non-clinical factors important, suggesting these may influence treatment independently of comorbid status or fitness for treatment. Disclosure J.M. Fitzpatrick: This study was funded by Sanofi-Aventis, L. Sharp: This study was funded by Sanofi-Aventis, M. De Camargo Cancela: This study was funded by Sanofi-Aventis, H. Comber: This study ws funded by Sanofi-Aventis

Published
2012
Full Text
View/download PDF

2. Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)

Author

S. Xiong, J. D. Wesley, F. Rolland, S. Chan, Bradley C. Carthon, L. G. Garcia, M. Fenner, Linda Sharp, Frank Priou, R. Morales-Barrera, W. Gerritsen, Bernhard J. Eigl, M. Tod, A.J.M. van den Eertwegh, Lawrence Fong, D. Baertschi, Arnoud J. Templeton, J.N. Graff, J. Morote, C. G. O'Bryan-Tear, Mert Basaran, S. Dixit, L. Mourey, J.P. Fusco, James B. Trager, C. Arbayo, Z. Peng, E. Solsona, D. D. Tsao-Wei, David P. Dearnaley, M. Hirmand, G. Procopio, M. Hancock, E. Verzoni, Eric Winquist, L. Shen, A. Sella, R. Tang, E. Ileana, J. A. Rinck, J.-G. Judde, B. Mellado, J. Simko, Martin E. Gleave, A. G. Caamano, Maha Hussain, Shaw Ling Wang, V. Ortega, L. Nicacio, Omar Esteban Carranza, D. G. Power, Frances P. Stewart, L. Bourre, Lawrence Karsh, B. Bennett, R. van Gool, S. Moran, M. Schulze, G. C. Cedermark, B. Esterni, Sophie D. Fosså, R. N. Dass, Guru Sonpavde, Anthony M. Joshua, B. A. Blumenstein, Christophe Massard, Andre Deeke Sasse, C. Suarez, D. Hawes, M. Marin-Aguilera, J. Lackey, M. Sharma, V. Pasov, J. T. Dalton, G. Velasco, G. Liu, J. Li, M. I. Murdock, D. Rathkopf, P. Vrignaud, R. Strebel, F. de Braud, Karim Fizazi, P. Raina, Linda Zinoli, V. De Angelis, A. J. Lloyd, B. Laguerre, S. Hitier, F. Vazquez, L. Zubiri, G. Maier, H. Lannert, M. A. Johnston, Stéphane Oudard, S.J. Hotte, X. Zhou, Nancy A. Dawson, Michael E. Cox, S. Donegani, M. Sisani, Jeffrey R. Gingrich, J. M. Ferrero, C. Papandreou, J. B. Whitmore, R. Sands, Q. Wang, Matthew R. Smith, C. Theodore, P. Perrin, P. M. Hoff, C. S.-L. Thibault, J.S. de Bono, J. Droz, Steinbjørn Hansen, M. A. Morgan, John M. Corman, P. Tryon, M. Climent, S. Berry, C. W. M. Reuter, A. Ozcimen, G. De Castro, T. Sella, G. Geiges, I. Kocak, U. Anido, Y. Hao, N. Bedini, Tanya B. Dorff, María E. Zudaire, David Smith, S. Li, Mansoor N. Saleh, M. Junqueira, I. Krakowski, Nadeem A. Sheikh, G. Sanchez-Olle, Raymond S. McDermott, G. Deplanque, Marianna de Camargo Cancela, L. Bellardita, W. Ye, R. Valdagni, J. Pinski, Nina Tunariu, C. Cavaliere, T. Devries, Silke Gillessen, Vasileios J. Assikis, Christopher J. Logothetis, K. Staudacher, A. Bahl, G. Chodak, R. Wei, Pasquale Rescigno, T. Shahid, M. Taplin, L. Ahrlund-Richter, Chadi Nabhan, N. Batista, Simon J. Hall, A. Heidenreich, Deborah Mukherji, Kim N. Chi, S. Zanetta, Ethan Basch, C. Kim, M. Haggman, Kurt Miller, S. Crowe, L. G. Fonseca, M. Nister, V. Grunwald, David I. Quinn, P. Cabrera, J. Wong, Peter F.A. Mulders, Noah M. Hahn, E. Levesque, W. Liu, Chris Parker, I. Gil-Aldea, I. Testa, Shahneen Sandhu, F. Ricci, N. Sacks, J. E. Brown, Eric J. Small, A. Ganser, C. Pezaro, S. Boccardo, E. Small, C. V. Morales, R. P. Taylor, Przemyslaw Twardowski, W. R. Clark, L. M. A. Aparicio, David Olmos, D. E. Castellano, Phillip Parente, R. Delva, A. Sanchez, Michael L. Meyers, A. Ruffion, P. Gascon, J. R. Gingerich, U. Harmenberg, D. Pouessel, Joshi J. Alumkal, L. Reyno, M. Spencer, S. Neibart, C. Korn, M. Habibian, Hazem I. Assi, J. Sarantopoulos, J. Charpentier, J. Squire, Christian Rothermundt, J. Versluis, G. Liskovsky, Saskia J. A. M. Santegoets, Maria Jose Lechuga, A. Hamzaj, E. Arevalo, Andrew J. Armstrong, Steven M. Larson, V. Naini, F. Kueppers, H. Ozen, R. Barroso-Sousa, C.J. Amling, Andrea L. Harzstark, L. Puglia, S. Bracarda, S. Le Moulec, S. Hubay, S. V. Liu, A. Horchani, L. Lui, F. Joly Lobbedez, S. Del Buono, S. Basu, N. Tiftik, D. Nicolle, P. de Souza, G. Freyer, T. Magnani, E. Benaim, E. Y. Yu, V. Yvonnet, N. Rozumna-Martynyuk, S. Salvi, P. Samper, M. S. N. M. Sharial, R. Salvioni, J. G. Gandhi, O. Terekhov, Elizabeth Eisenhauer, G. Gravis, I. Bodrogi, J. Lin, I. N. Boyko, B. Zhang, Patricia Martin, S. Kovel, Eleni Efstathiou, A. Cross, S. Villa, Cora N. Sternberg, Vivian Weinberg, M. Soulie, J. Zou, M. Wilbaux, David B. Agus, Yohann Loriot, C. Goessl, A. Stam, I. De Torres, D. W. Davis, M. Hjelm-Eriksson, P. Federico, J. E. Garcia-Vargas, M. Gedamke, Philip W. Kantoff, A. Petremolo, F. Marrocolo, B. Perez-Valderrama, G. Mordenti, X. Maldonado, P. Hamberg, Roberto Pili, M. Doherty, K. Hege, Pier Vitale Nuzzo, Winald R. Gerritsen, D. P. Petrylak, L. Ji, O. A. Sartor, Leonard G. Gomella, Sumanta K. Pal, J. Bruce, Scott North, Mario A. Eisenberger, Robert E. Coleman, Diletta Bianchini, E. Henin, Michael A. Carducci, A. G. Omlin, S. De Placido, A. Liede, J. Good, A. Hartford, Richard Cathomas, Anna C. Ferrari, S. S. Sridhar, Alessandra Rubagotti, A. C. R. Chaves, P. Sieber, L. O. Reis, D. Lin, A. Arican, Y. Zhang, O. Nordle, J. Tito, G. Bhattacharyya, V. Melnikova, N. Aucoin, P. W. Price, Susan Ellard, P. Beuzeboc, K. Noonan, A. A. Ranade, M. W. Frohlich, B. Anand, K. Buyukafsar, William R. Berry, Mitchell S. Steiner, D. Raghavan, Daniel J. George, C. D. L. Piedra, Gregory R. Pond, F. Acosta, A. O. Sartor, A. Yildirim, G. Di Lorenzo, Thomas W. Griffin, P. M. Parikh, Harry Comber, Matthew D. Galsky, A. J. Armstrong, J. M. Fitzpatrick, M. Legrier, J. R. Piulats, Neal D. Shore, Walter M. Stadler, J. Powers, R. J. Amato, S. O'Reilly, G. B. Kanaka, M. Girard, N. Nicolai, D. Maillet, C. Piatek, Robert H. Getzenberg, Dana E. Rathkopf, J. Eymard, E. C. Alvarez, S. Wong, H. Kurt, Elisabeth I. Heath, R. C. Winterhalder, T. Zoubir, A. Tagliapietra, I. N. Hernandez, Oliver Sartor, H. Malhotra, Amir Goldkorn, E. J. Leonard, J. M. Wolff, Ronald F. Tutrone, Charles S. Cleeland, Q. Perez, A. Ulyanov, Christopher Sweeney, Mustafa Ozguroglu, Jolanda Paolini, I. Lowy, Ignacio Gil-Bazo, C. Dzik, Fred Saad, William Oh, L. Skoog, S. Stagni, Emmanuel S. Antonarakis, Maria J. Ribal, C. L. Nourani, E. Chow-Maneval, J-P. Machiels, K. Anderes, Shannon Matheny, T. de La Motte Rouge, A. Ata, Celestia S. Higano, Malcolm David Mason, Heather Haynes, L. Sengelov, M. Poupon, S. Nilsson, K. Jelaca-Maxwell, R. A. Stephenson, Thian Kheoh, Howard I. Scher, S. Groshen, P. Schellhammer, Y. Pawitan, C. Li, C. D'Aniello, A. Olsson, Michael Pollak, T. Harding, I. Latorzeff, Ralph J. Hauke, Arturo Molina, Paul N. Mainwaring, J. J. Lozano, F. McDonnell, B. You, R. B. Sims, P. Carroll, Z. I. Malik, Joan Carles, Ainhoa Castillo, D. T. Castro, M.D. Michaelson, T.D. de Gruijl, Joaquim Bellmunt, N. Houede, Manisha Singh, A. Guillot, A. M. Cassidy, Charles J. Ryan, E. Esteban, M. Truini, Laurence Albiges, C. Buonerba, O. Gunther, G. Forsberg, Bryan Selby, Paul G. Corn, B. A. Wood, J. K. Singh, Michael J. Morris, J. Biswas, M. Gross Goupil, Francesco Boccardo, W. de Schultz, P. Czaykowski, Nicholas J. Vogelzang, M. Y. Teo, P. Afzal, and Gerhardt Attard

Subjects
medicine.medical_specialty, Genitourinary system, business.industry, Standard treatment, Hazard ratio, Urology, Hematology, medicine.disease, Androgen deprivation therapy, Prostate cancer, medicine.anatomical_structure, Oncology, Docetaxel, Prostate, medicine, Clinical endpoint, business, medicine.drug
Abstract

Background Androgen deprivation therapy (ADT) is the standard treatment of hormone-sensitive metastatic prostate cancer (HSMPC). We performed a phase III multicentre trial to compare ADT alone with ADT plus docetaxel (D) in HNMPC. Methods Patients (pts) with HSMPC were randomly assigned to either arm A (ADT + D: 75mg/m q3w, up to 9 cycles) or arm B (ADT). The primary endpoint was overall survival (OS). The planned number of pts was 378 to detect an improvement in OS with a hazard ratio (HR) of 0.62, a power of 80% and an alpha risk of 0.05 (two-sided test). Secondary endpoints were biological progression-free survival (PFS) and clinical PFS. Data on toxicity and quality of life have been previously presented. Results From October 2004 to December 2008, 385pts were included. Baseline characteristics were well balanced between the two arms. Median age was 63 years (43-84), median PSA was 26.4 ng/ml (0.1-11900), Gleason score was ≥ 8 in 57%. Prognostic classification was as follows: good prognosis (49%), intermediate (29%) and poor (22%). The majority of pts had metastases at the time of diagnosis (72%), 28% developed metastases after local treatment failure. Median number of D cycles was 8 (range 0-9). The median follow-up was 50 months (mo) [95%CI: 49-54]. At 6 mo, a higher PSA response (≥ 50%) in arm A (94% vs 85%, p = 0.0096) and a higher PSA progression (≥ 25%) in arm B (10% vs 1%, p = 0.0015) were observed. Biological PFS was significantly longer in arm A: 22.9 vs 12.9 mo, HR; 0.72 [95%CI: 0.57-0.91] (p = 0.005). Clinical PFS was increase in arm A: 23.46 vs 15.44 mo, HR: 0.75 [95CI: 0.59-0.94] (0.015). OS was not significantly different (median: 58.9 mo in arm A and 54.2 mo in arm B, HR: 1.01 [95%CI: 0.75-1.36]. The median OS for each prognostic group was 69.1 [95%CI: 60.9-NR], 46.5 [95%CI: 37.7-NR] and 36.6 [95%CI9: 28.5-58.9] mo respectively in the good, intermediate, and poor prognosis groups (p = 0.001), with no difference between the two arms. At the cut-off time, 65% of pts from the ADT arm had received docetaxel since they developed castrate-resistant prostate cancer. Conclusion Combining docetaxel and ADT improves PFS over ADT alone in pts with HSMPC. However, no difference in OS was observed between the two arms. Disclosure G. Gravis: I have expert testimony to disclose: Sanofi Aventis, uncompensated. K. Fizazi: Participation to advisory boards and speaker for Sanofi-Aventis. F. Joly Lobbedez: advisory board/board of directors position: Sanofi, Roche, Pfizer, Novartis, Ferring; compensated consultant relationship: Roche, Novartis; honoraria: Sanofi, Roche, Pfizer, Novartis, Ferring, Ipsen,Takeda; travel remuneration: ASCO by Novartis, ESMO by Janssen. S. Oudard: I have an advisory relationship and honoraria to disclose: Pfizer Oncology, Bayer-Schering Pharma, Hoffman La Roche, Glaxo SmithKline, Novartis Pharma, Sanofi Aventis. D. Pouessel: Consultant role and honoraria: Sanofi, P. Beuzeboc: Presentations: Avantis, All other authors have declared no conflicts of interest.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results